-
- 抗原 See all LYVE1 抗体
- LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))
-
适用
- 小鼠
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This LYVE1 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Acetone-fixed) (IHC (af))
- 原理
- Lyve-1 antibody
- 特异性
- Recombinant mouse soluble Lyve-1
- 产品特性
-
Chromosomal location: 7, 7F2
Produced from sera of rabbits immunized with highly pure recombinant mouse soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis). - 纯化方法
- Protein-A purified
- 免疫原
- Recombinant mouse soluble Lyve-1 (ABIN1589750)
- 亚型
- IgG
- Top Product
- Discover our top product LYVE1 Primary Antibody
-
-
- 应用备注
- Western Blot: use at 2-5 μg/mL, FACS: use at 3-10 μg/mL, IF/IHC: applicable with cryo-sections.
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.
- 缓冲液
- PBS
- 注意事项
- Centrifuge vial prior to opening.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
- 有效期
- 24 months
-
-
The lymphatic vascular system of the mouse head." in: Cell and tissue research, (2016) (PubMed).
: "Medicinal facilities to B16F10 melanoma cells for distant metastasis control with a supramolecular complex by DEAE-dextran-MMA copolymer/paclitaxel." in: Drug delivery and translational research, Vol. 5, Issue 1, pp. 38-50, (2015) (PubMed).
: "TGF-?1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis." in: Oncogene, (2015) (PubMed).
: "Endothelial, but not smooth muscle, peroxisome proliferator-activated receptor ?/? regulates vascular permeability and anaphylaxis." in: The Journal of allergy and clinical immunology, Vol. 135, Issue 6, pp. 1625-35.e5, (2015) (PubMed).
: "Arterial wall lymphangiogenesis is increased in the human iliac atherosclerotic arteries: involvement of CCR7 receptor." in: Lymphatic research and biology, Vol. 12, Issue 4, pp. 222-31, (2014) (PubMed).
: "Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model." in: Clinical & experimental metastasis, Vol. 31, Issue 3, pp. 351-65, (2014) (PubMed).
: "The effect of podoplanin inhibition on lymphangiogenesis under pathological conditions." in: Investigative ophthalmology & visual science, Vol. 55, Issue 8, pp. 4813-22, (2014) (PubMed).
: "Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties." in: Cancer research, Vol. 74, Issue 11, pp. 2999-3010, (2014) (PubMed).
: "Rapamycin inhibition of CFA-induced lymphangiogenesis in PLN is independent of mast cells." in: Molecular biology reports, Vol. 41, Issue 4, pp. 2217-28, (2014) (PubMed).
: "Clonal analysis identifies hemogenic endothelium as the source of the blood-endothelial common lineage in the mouse embryo." in: Blood, Vol. 124, Issue 16, pp. 2523-32, (2014) (PubMed).
: "Lymphatic drainage pathways from the cervix uteri: implications for radical hysterectomy?" in: Gynecologic oncology, Vol. 132, Issue 1, pp. 107-13, (2014) (PubMed).
: "Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 192, Issue 11, pp. 5002-11, (2014) (PubMed).
: "Apelin promotes lymphangiogenesis and lymph node metastasis." in: Oncotarget, Vol. 5, Issue 12, pp. 4426-37, (2014) (PubMed).
: "Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages." in: PLoS ONE, Vol. 9, Issue 6, pp. e99568, (2014) (PubMed).
: "Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis." in: Angiogenesis, Vol. 17, Issue 2, pp. 347-57, (2014) (PubMed).
: "
-
The lymphatic vascular system of the mouse head." in: Cell and tissue research, (2016) (PubMed).
-
- 抗原
- LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))
- 别名
- Lyve-1 (LYVE1 产品)
- 别名
- LYVE1 antibody, XLKD1 antibody, CRSBP-1 antibody, HAR antibody, LYVE-1 antibody, 1200012G08Rik antibody, Crsbp-1 antibody, Lyve-1 antibody, Xlkd1 antibody, lymphatic vessel endothelial hyaluronic receptor 1a antibody, lymphatic vessel endothelial hyaluronan receptor 1 antibody, lyve1a antibody, LYVE1 antibody, Lyve1 antibody
- 背景
- Lyve1, Xlkd1, Lyve-1, Crsbp-1, 1200012G08Rik,LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41 % similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 Molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 Molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
- 基因ID
- 114332
- NCBI登录号
- NM_053247, NP_444477
- UniProt
- Q8BHC0
- 途径
- Glycosaminoglycan Metabolic Process
-